Brought to you by 
Complix raises €12mm through Series B round
19 Jan 2016
Executive Summary
Complix NV (protein therapeutics for cancer and autoimmune diseases) raised €12mm ($15.5mm) through its Series B round co-led by new investors Edmond de Rothschild Investment Partners, GIMV, and Biotech Fund Flanders (managed by GIMV). LRM, Omnes Capital, Vesalius Biocapital, Gemma Frisius Fund, TrustCapital, Vinnof, Baekeland Fund, CRP-Santé, and members of Complix’s management also participated. One executive from Edmond de Rothschild and GIMV will join the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Complix raises €12mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice